Watch as Muhamed Baljević, MD, director of the Plasma Cell Disorders Research at Vanderbilt-Ingram Cancer Center, joins OBR host and patient advocate, Michele Nadeem-Baker, to talk about the “active and eventful” CAR T-cell therapy studies presented at the 2022 ASH Annual Meeting and how the findings will affect treatment of multiple myeloma. Dr. Baljević highlights several key abstracts including the study of CART-Ddcbma (Abstract 3313). Also, Dr. Baljević talks about the need for different CAR T targets and whether real world outcomes match those of the latest trials.
Dr. Baljević reports relationships with BMS/Celgene Corporation, Cardinal Health Specialty Solutions, CurioScience, Janssen Research & Development, Karyopharm Therapeutics, Oncopeptides, and Sanofi-Gensyme.
